The new Chinese autoimmune studies, part of Ipsos’ syndicated global therapy monitor portfolio, will incorporate real patient record data with doctors’ perceptions to analyse the market landscape, market shares, reasons behind treatment trends and potential impact of products in development.

It will complement Ipsos Healthcare’s existing real world evidence offer in China, which covers oncology, diabetes, cardiovascular, respiratory and virology diseases.

Subscribers will get an in-depth analysis of the various factors shaping treatment choice in these indications, including drivers for and barriers to the uptake of biologics.

Pieter De Richter, regional head of APAC syndicated at Ipsos Healthcare, said: “The uptake of biologics for the treatment of autoimmune diseases has been slower in China than in established markets such as the US and Europe. However, the large number of patients suffering from these often debilitating conditions, linked to continuous improvements in reimbursement cover and access, present a huge opportunity for pharma companies offering effective and well-tolerated therapies.”